Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4634680PMC
http://dx.doi.org/10.1111/j.1750-2659.2009.00092.xDOI Listing

Publication Analysis

Top Keywords

'novel' influenza
4
influenza ah1n1
4
ah1n1 enigma
4
enigma pandemic
4
pandemic respond
4
respond call
4
call it?
4
'novel'
1
ah1n1
1
enigma
1

Similar Publications

The PA-X host shutoff site 100 V exerts a contrary effect on viral fitness of the highly pathogenic H7N9 influenza A virus in mice and chickens.

Virulence

December 2025

Key Laboratory of Avian Bioproducts Development, Ministry of Agriculture and Rural Affairs, Yangzhou, China.

Several viruses, including influenza A virus (IAV), encode viral factors to hijack cellular RNA biogenesis processes to direct the degradation of host mRNAs, termed "host shutoff." Host shutoff enables viruses to simultaneously reduce antiviral responses and provides preferential access for viral mRNAs to cellular translation machinery. IAV PA-X is one of these factors that selectively shuts off the global host genes.

View Article and Find Full Text PDF

CD4 T cells play a pivotal role in the immune system, particularly in adaptive immunity, by orchestrating and enhancing immune responses. CD4 T cell-related immune responses exhibit diverse characteristics in different diseases. This study utilizes gene expression analysis of CD4 T cells to classify and understand complex diseases.

View Article and Find Full Text PDF

Evidence of an emerging triple-reassortant H3N3 avian influenza virus in China.

BMC Genomics

December 2024

The Key Lab of Animal Disease and Public Health / Luoyang Key Laboratory of Live Carrier Biomaterial and Animal Disease Prevention and Control, Henan University of Science and Technology, Luoyang, Henan, 471023, China.

The H3 subtype of avian influenza virus (AIV) stands out as one of the most prevalent subtypes, posing a significant threat to public health. In this study, a novel triple-reassortant H3N3 AIV designated A/chicken/China/16/2023 (H3N3), was isolated from a sick chicken in northern China. The complete genome of the isolate was determined using next-generation sequencing, and the AIV-like particles were confirmed via transmission electron microscopy.

View Article and Find Full Text PDF

Lipid nanoparticles encapsulating both adjuvant and antigen mRNA improve influenza immune cross-protection in mice.

Biomaterials

December 2024

Center for Inflammation, Immunity & Infection, Institute for Biomedical Science, Georgia State University, Atlanta, GA, USA. Electronic address:

The rapid approval of SARS-CoV-2 mRNA lipid nanoparticle (LNP) vaccines indicates the versatility of mRNA LNPs in an urgent vaccine need. However, the mRNA vaccines do not induce mucosal cellular responses or broad protection against recent variants. To improve cross-protection of mRNA vaccines, here we engineered a pioneered mRNA LNP encapsulating with mRNA constructs encoding cytokine adjuvant and influenza A hemagglutinin (HA) antigen for intradermal vaccination.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!